Capricor Therapeutics Inc. (NASDAQ:CAPR) does about 2.61M shares in volume on a normal day but saw 4184726 shares change hands in Tuesday trading. The company now has a market cap of 113.51M USD. Its current market price is $5.71, marking an increase of 3.63% compared to the previous close of $5.51. The 52 week high reached by this stock is $12.32 whilst the lowest price level in 52 weeks is $0.88. The script in recent trading has seen the stock touch a high of $6.20 and a low of $5.55.
Capricor Therapeutics Inc. (CAPR) has a 20-day trading average at $6.84 and the current price is -53.65% off the 52-week high compared with 548.86% distance from its 52-week low. The 50-day simple moving average of the closing price is $5.95 and its 200-day simple moving average is $3.30. If we look at the stock’s price movements over the week, volatility stands at 7.74%, which increases to 14.69% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 43.58 to suggest the stock is neutral.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 26, 2018 when Maxim Group downgraded the stock to “Hold” and issued a price target of. H.C. Wainwright reiterated its price target at $2.15-$6.50.
The current price level is -18.80%, -3.64%, and 74.00% away from its SMA20, SMA50, and SMA200 respectively, with the CAPR price moving above the 50-day SMA on August 25. Capricor Therapeutics Inc. (CAPR) stock is down -12.29% over the week and -41.79% over the past month. Its price is 346.09% year-to-date and 111.48% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.23 above consensus estimates by $0.14. The company’s next earnings report is expected on 11/05/2020, with forecasts estimating quarterly EPS at -$0.37 and -$1.46 for whole year. CAPR’s earnings per share are forecast to grow by 29.10% this year and 36.30% over next year. Expected sales for next quarter are $210k, which analysts say will come at $570k for the current fiscal year and next year at $900k. In addition, estimates put the company’s current quarterly revenue at an average of $210k.
Outstanding shares total 19.72M with insiders holding 9.21% of the shares and institutional holders owning 3.69% of the company’s common stock. The company has a return on investment of -75.80% and return on equity of -66.90%. The beta has a value of 7.23. Price to book ratio is 2.73 and price to sales ratio is 189.19.
According to a U.S. Securities and Exchange Commission filing, Vanguard Extended Market Index Fu has added its position in Capricor Therapeutics Inc. (CAPR) to 76,500 shares, mirroring a recent increase by 69.93%. Vanguard Extended Market Index Fu added 31481.0 shares of Capricor Therapeutics Inc. common stock bringing its total worth to about $0.61 million at the end of recent close, SEC documents show. Vanguard Extended Market Index Fu isn’t the only investment manager who changed stakes and is followed by iShares Tr – Micro Cap ETF, which sold off 0.0 shares to end up with 30,067 shares worth $0.24 million. Fidelity Extended Market Index Fu cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.12% position in Capricor Therapeutics Inc. thanks to 17272.0 shares amounting to $0.14 million.